At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Estradiol 100 Micrograms Patch +1 moredrug
Likely dose
Estradiol 100 Micrograms Patchfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact of Individualized Estrogen Therapy on Cardiovascular Disease Risk Parameters in Young Women After Bilateral Oophorectomy: A Randomized Controlled Trial
In Brief
A Phase 2 clinical trial evaluating Estradiol 100 Micrograms Patch and Estradiol Patch for Cardiovascular Risk Reduction. Completed, enrolled 35 participants across 1 site.
Detailed Summary
Researchers are trying to assess the appropriate dose of estrogen for decreasing the risk of cardiovascular disease in women who have removal of their ovaries at a young age, before the age of 46 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Risk Reduction
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartMar 2019
Primary CompletionAug 2023
TodayJul 2026
First PostedJan 24, 2019
Enrollment StartMar 15, 2019
Primary CompletionAug 28, 2023
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 7.4 years ago
Interventions
Estradiol 100 Micrograms Patchdrug
Standard
Estradiol Patchdrug
Individualized